Onconetix to Acquire Realbotix, Pivot to Humanoid AI

Onconetix ( (ONCO) ) just unveiled an update.

On February 11, 2026, Onconetix entered a definitive share exchange agreement to acquire all of Realbotix LLC in an all-stock deal, with closing targeted for the second half of 2026 and Realbotix’s parent expected to own 75% to 90% of the combined company depending on Onconetix’s net cash at completion. The transaction, which will shift Onconetix’s strategic focus from biotech toward embodied AI and humanoid robotics and install Realbotix Corp CEO Andrew Kiguel as CEO of the combined Nasdaq-listed entity, is subject to customary conditions including shareholder and regulatory approvals, and is intended to capitalize on Realbotix’s early commercial traction and leadership in lifelike autonomous robots while significantly diluting existing Onconetix shareholders and introducing integration and execution risks.

Realbotix brings a portfolio of AI-enabled humanoid robots already deployed with marquee clients and high-visibility pilots, including customer-service and brand-representation roles at venues such as Fashion Show Mall in Las Vegas, the Bitcoin Conference, Ericsson Innovation and media outlets like Fox Business and CNN in 2024–2025. The company has rapidly expanded its technology stack with multilingual capabilities, a proprietary robotic vision system, integration of major third-party LLMs, and live demonstrations of fully autonomous, unscripted multi-language robot-to-robot conversations at CES 2026, positioning the combined business to tap into a fast-growing humanoid robotics market while exposing Onconetix investors to substantial technology, market, dilution and integration-related risks outlined by the buyer.

Spark’s Take on ONCO Stock

According to Spark, TipRanks’ AI Analyst, ONCO is a Underperform.

Onconetix’s overall score reflects substantial financial difficulties with significant operating losses and negative profitability metrics. The technical analysis suggests a bearish trend, and the valuation metrics are unfavorable due to negative earnings. These factors combine to give the stock a low attractiveness score.

To see Spark’s full report on ONCO stock, click here.

More about Onconetix

Onconetix, Inc., formerly Blue Water Biotech, is a commercial-stage biotechnology company focused on oncology, with its key product Proclarix, an in vitro diagnostic test for prostate cancer sold in the EU and expected to be offered as a lab-developed test in the U.S. through a Labcorp license. Realbotix LLC, based in Las Vegas and currently a subsidiary of Realbotix Corp., develops and manufactures AI-powered, highly customizable humanoid robots for customer-facing roles in healthcare, education, hospitality and entertainment, leveraging patented lifelike hardware and an AI-agnostic platform that integrates both proprietary and third-party large language models.

Average Trading Volume: 80,179

Technical Sentiment Signal: Sell

Current Market Cap: $2.35M

See more data about ONCO stock on TipRanks’ Stock Analysis page.